Risk factors

Capital access disclosures now explicitly cite acquisitions of FBM and ADG and lender reputation.

MAIA added significant risk disclosures regarding its new corporate treasury policy of acquiring and staking digital assets like Solana.

The company has no product revenue and reported approximately $7.8 million in cash at December 31, 2025.

Increased focus on artificial intelligence integration risks and evolving regulatory compliance requirements for satellite operations. Growing net operating loss carryforwards to $967.3 million alongside persistent GAAP net operating losses. Expanded competition naming specific players like Apple, Google, and Microsoft across commercial and government sectors.

This company filing contains no risk factors, as no new, dropped, or reworded risks are present.

Pyxis Oncology highlights ongoing going-concern doubts, heavy reliance on its lead candidate MICVO, and manufacturing risks tied to China suppliers.

Richmond Mutual Bancorporation is expanding via the Farmers Bancorp merger, increasing integration and execution risks this year.

Solo Brands faces going concern doubts driven by heavy debt, restructuring efforts, and past NYSE delisting warnings.

SilverBox Corp V faces typical blank check company risks, focusing on search, business combination execution, and potential liquidation. Key risks include heavy reliance on management, lack of target information, potential redemptions, and complex cross-border or financing challenges.

AI semiconductor demand is increasingly concentrated among hyperscalers, creating exposure to rapid technology shifts, competition, and production ramp constraints.

Sutro Biopharma restructured in March and September 2025, shifting entirely to third-party contract manufacturers for product supply.

New going concern doubts and heavy reliance on external financing dominate the risk profile.